Inhibiting TGF-β activity improves respiratory function in mdx mice.

Area of Science:

• Biomedical Research
• Translational Medicine
• Musculoskeletal Disorders

Background:

• Respiratory dysfunction is a primary cause of mortality in Duchenne muscular dystrophy (DMD).
• Elevated transforming growth factor-beta (TGF-β) levels are implicated in DMD pathophysiology.
• Investigating therapeutic strategies to counteract TGF-β signaling is crucial for DMD treatment.

Purpose of the Study:

• To evaluate the efficacy of TGF-β signaling inhibition in improving respiratory function in mdx mice, a model for DMD.
• To compare the effects of a TGF-β neutralizing antibody (1D11) and losartan (an angiotensin receptor antagonist) on respiratory and muscle parameters.

Main Methods:

• mdx mice were treated with 1D11, losartan, or a combination from 2 weeks to 2 or 9 months of age.
• Respiratory function was assessed using non-invasive plethysmography.
• Muscle strength (forelimb grip), serum creatine kinase, diaphragm muscle fiber density, and hydroxyproline levels were measured.

Main Results:

• All tested treatments normalized respiratory parameters ( Penh values, breathing frequency, inspiratory flow) in mdx mice.
• 1D11 treatment improved forelimb grip strength at both 2 and 9 months, while losartan's effect was limited to 2 months.
• Significant improvements in serum creatine kinase and diaphragm muscle fiber density were observed across all treatment groups, with 1D11 showing superior results in reducing hydroxyproline levels.

Conclusions:

• Therapeutic antagonism of TGF-β signaling effectively improves respiratory and muscle function in a mouse model of DMD.
• 1D11 demonstrated comparable or superior efficacy to losartan, suggesting TGF-β antagonism as a viable therapeutic approach for DMD.
• Combination therapy did not provide additional benefits over 1D11 alone.